This is not just another tool to image cancer. The probe is a two-for-one: detect cancer and distinguish one type from another. Together, they develop a cancer fingerprint.
Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers at Michigan Technological University hope to reduce that timeframe down to minutes.
A collaborative team of chemists and engineers from Michigan Tech lays the groundwork for this vision in two new papers. In the Royal Society of Chemistry’s journal Chemical Communication (DOI: 10.1039/c7cc09809j), the team explains the basic science behind multicolor probes that enable targeting of a cancer-relevant fructose transporter, delving into the image-based detection of cancer cells. In the journal Biosensors (DOI: 10.3390/bios8020039), the team addresses applications for breast cancer detection and differentiating nonmalignant, pre-malignant and malignant cancer cells.
GLUT5 transports fructose and cancer loves sugar
Two Michigan Tech researchers collaborated on the studies. Marina Tanasova, assistant professor of chemistry, and Smitha Rao, assistant professor of biomedical engineering, turned a 10-minute office meeting into a two-year collaboration built on a tiny fluorescent probe that seeks out the fructose transporter named GLUT5.
Cells need carbohydrates; facilitative glucose transporters (GLUTs) bring nutrients in and out of cells. When metabolic swings kick in—say, from cancer development—the overall make-up of GLUTs change so that more or less GLUTs are active. Fructose transporters like GLUT5 are of particular interest because of the direct connection between fructose uptake and cancer development, which also changes as cancer progresses and becomes malignant.
In their Chemical Communications paper, Tanasova and Rao’s team report on the design and validation of the fluorescent probes, called ManCous, to observe GLUT5 activity in a cell. They document the multicolored fluorescence that distinguishes GLUT5-rich cells from those deficient in GLUT5. The follow up Biosensors paper provides a proof-of-principle use of these probes as tools to assess and compare GLUT5 and metabolic activity of different cell types, including normal cells and different cancer subtypes.
“We came closer to a basic screening of cells’ GLUT composition—one that both detects cancer and distinguishes type,” Tanasova says, adding that while the concept is elegant, developing the technology is not easy. “From basic science to application, there is a lot of transformation that has to happen.”
Engineering better cancer detection takes collaboration
By better understanding the science behind sugar transporters, the team is more equipped to build technology that captures an accurate and precise GLUT fingerprint of cancerous cells.
“This probe is like a Swiss army knife,” Rao says, explaining that cancer detection is not the only use for the probe. “The more we learn about cancer through these probes, the more opportunities we have to apply them—which means more chances to treat different cancers, hopefully cure them, and at least prevent their spread and maximize drug delivery.”
What makes the probe so versatile is its ability to not only seek out and highlight cancer cells, but also to reveal the metabolic nuances of different stages of cancer development. While cancer generally gobbles up fructose, the GLUT5 and metabolic activity of nonmalignant, pre-malignant and malignant breast cancer cells do vary, which is what Rao, Tanasova and their team explored in the Biosensors paper. They found that ManCou probes allow for parallel analysis and quantification of GLUT5 and metabolic activity of cells just after a 10-minute incubation period. The notable differences in fluorescence intensity observed between normal cells and cancer cells, as well as different cancer types, provide important points of differentiation between different cell types and make these probes promising tools for cancer detection and diagnostics.
The Latest on: Cancer fingerprint
via Google News
The Latest on: Cancer fingerprint
- Transposable element expression in tumors is associated with immune infiltration and increased antigenicityon November 19, 2019 at 8:34 am
These features are potentially cancer transcriptional fingerprints and may provide insights for future therapies. Distinct sequences representing GENCODE RE-containing introns (n = 185,403) and ...
- Al Murray urges Sun readers to become blood stem cell donors — as his six-year-old nephew fights canceron November 14, 2019 at 3:07 pm
Someone in the UK is diagnosed with a blood cancer, such as a leukaemia, lymphoma or myeloma ... It’s much more fundamental to your DNA. It’s not quite fingerprints but it’s on that level, so that’s ...
- Pioneering new 'smart needle' could revolutionize cancer diagnosison November 11, 2019 at 7:55 am
The results show it is possible to show a fingerprint of the disease that can be used to diagnose cancer within a few seconds, producing near instantaneous results for the clinician and reducing ...
- ‘Smart needle’ could speed up cancer diagnosis rates, scientists sayon November 11, 2019 at 5:44 am
They say light from the laser is scattered differently depending on whether the tissue is healthy or diseased, providing doctors with a fingerprint for the cancer. “The Raman smart needle can measure ...
- Sen. Blumenthal calls on Uber, Lyft to share data on risky drivers, implement fingerprintingon November 8, 2019 at 6:47 am
Lyft spokesman Adrian Durbin didn't respond to a request for comment. [Politics] State Rep. Linda Orange to resign from legislature after cancer diagnosis » In their responses to Blumenthal, both Uber ...
- Genetic 'fingerprint' may ID breast cancer patients likely to benefit from potentially toxic chemo, study findson November 8, 2019 at 4:27 am
Women with early-stage breast cancer that has a specific pattern of gene expression are more likely than others to benefit from treatment with a class of common but potentially harmful chemotherapy ...
- New DNA ‘Fingerprint’ Test Predicts Response To Toxic Breast Cancer Drugson November 7, 2019 at 2:14 pm
New research has shown that it may be possible to predict whether women with breast cancer will ... [+] respond to commonly-used chemotherapy drugs. Getty Researchers from Stanford University in ...
- Global Management Report 2019: Innovations in Cancer, Cardiovascular, and Neurological Diseases - ResearchAndMarkets.comon November 7, 2019 at 10:04 am
The "Innovations for the Management of Cancer, Cardiovascular ... TechVision Opportunity Engine profiles advancements in wearable sensors, pressure sensors, fingerprint sensors, ultrasonic sensors, ...
- New cancer treatment provides woman hopeon November 5, 2019 at 8:50 pm
“Cancer genomics are as unique as a person’s fingerprint,” Dr. Sara Taylor, a medical oncologist practising in Kelowna, told a fundraising luncheon Tuesday in support of the BC Cancer Foundation.
via Bing News